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The ability to target therapeutic agents to specific tissues is an important element in the
development of new disease treatments. The transferrin receptor (TfR) is one potential tar-
get for drug delivery, as it expressed on many dividing cells and on brain endothelium, the
key cellular component of the blood-brain barrier. The aim of this study was to compare a
set of new and previously-described polypeptides for their ability to bind to brain endothe-
lium, and investigate their potential for targeting therapeutic agents to the CNS. Six polypep-
tides were ranked for their rate of endocytosis by the human brain endothelial cell line
hCMEC/D3 and the murine line bEnd.3. One linear polypeptide and two cyclic polypeptides
showed high rates of uptake. These peptides were investigated to determine whether
serum components, including transferrin itself affected uptake by the endothelium. One of
the cyclic peptides was strongly inhibited by transferrin and the other cyclic peptide weakly
inhibited. As proof of principle the linear peptide was attached to 2nm glucose coated gold-
nanoparticles, and the rate of uptake of the nanoparticles measured in a hydrogel model of
the blood-brain barrier. Attachment of the TfR-targeting polypeptide significantly increased
the rates of endocytosis by brain endothelium and increased movement of nanoparticles
across the cells.
Introduction
The targeting of therapeutic agents to specific cells or tissues is central to the development of
treatments for many diseases. Increasing the proportion of a drug that reaches the target-tissue
reduces potential off-target effects and the dose required to produce a therapeutic effect. This
latter point is particularly important as expensive biological agents are increasingly being
developed for clinical use. The main approach to targeting has been to identify receptors that
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‘Delivery of therapeutic cytokines to the CNS, using
are expressed on the target cell and develop antibodies, peptides or aptamers that bind to that
receptor and which may be coupled to a therapeutic agent [1–4].
The transferrin receptor (TfR) is a particularly attractive target as it is expressed on many
dividing cell-types and has therefore often been chosen for targeting tumour cells [5, 6]. In
addition, the TfR is highly expressed on brain capillary endothelium, where it acts as an essen-
tial transporter of iron to the brain [7–9]. Expression on other vascular endothelial cells is rela-
tively low [10]. Delivering therapeutics to the brain is especially problematic because of the
blood-brain barrier (BBB) [3, 11]. The majority of drugs with potential to treat brain diseases
cannot cross the barrier [12] and none of the large therapeutic biomolecules (cytokines, anti-
bodies, siRNA etc), can pass through the tight junctions between brain endothelial cells [13].
As the TfR enables endocytosis and transcytosis of transferrin (Tf) a large serum protein
(80kDa), it could also theoretically be used to transport therapeutic agents into the brain [14].
It has been debated as to what proportion of the TfR undergoes transcytosis, is recycled to the
apical membrane or is degraded in endosomal compartments. Indeed, the intracellular fate of
the Tfr partly depends on the bound ligand. Nevertheless this receptor does have potential for
transport of large therapeutic biomolecules.
Several targeting systems have been developed that aim to use the TfR for transport to the
brain, including antibodies, antibody fragments and peptides [7, 14, 15]. These targeting
agents have been isolated from libraries by a variety of techniques, including direct-binding to
the TfR. Interestingly divalent antibodies with high affinity for the TfR are not necessarily
most effective in promoting transcytosis, as the receptor can be diverted to lysosomal pathways
by the binding of high-affinity ligands and/or cross-linking [16]. Ideally a reagent that targets
the TfR should be small, easy to attach to the cargo-molecules or nanoparticles that are being
transported and not interfere with endosomal transport. Polypeptides can fulfil many of these
requirements [17] and various approaches have been made to develop brain-targeting peptides
[18–20].
The aim of this study was to compare the properties of a number of different peptides that
bind to the TfR, including a linear peptide [21] and three recently-described cyclic peptides
isolated from a phage-display library by binding to murine and human TfR [22]. It was partic-
ularly notable that one of these cyclic peptides has primary sequence homology with a cyclic
peptide isolated by binding to brain endothelium in vivo, from a much older study [23].
This work compares the rate of endocytosis of the polypeptides after binding to the human
brain endothelial cell line hCMEC/D3. One important consideration in developing peptides
that bind the TfR is that they should still be active in the presence of serum molecules, includ-
ing Tf itself. Ideally Tf and the polypeptide would bind separate sites on the TfR. This would
also ensure that using the peptide to aid drug transport would reduce potential interference
with the normal iron transport system of the brain. Hence another element of the study was to
assess peptide interaction with brain endothelium in the presence of different amounts of
serum or Tf. The study has identified important properties and distinct differences between




The polypeptides were produced by Peptide Synthetics (Fareham, UK) and purity confirmed
by mass spectrometry (>95%). Cyclic peptides were tagged with Fitc at the N-terminus and
the linear peptide at the C-terminus, to allow tracking. Spacers (GA) were added to the original
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sequences in order to reduce the possibility that the Fitc would interfere with TfR-binding
(Table 1).
Additional data on these peptides is given in S1 Table. Peptides were dissolved in dimethyl
sulfoxide at 10mg/ml and stored in aliquots at -80˚C until use at 1–10μg/ml in Hank’s bal-
anced salt solution (HBSS) with the stated amounts of foetal bovine serum (FBS).
Cell cultures
The human brain endothelial line hCMEC/D3, originally characterised in this laboratory [24]
was used at passage 24–33 and cultured in modified EBM-2 MV medium (Lonza) containing
(v/v) 0.025% VEGF, IGF and EGF, 0.1% bFGF, 0.1% rhFGF, 0.1% gentamycin, 0.1% ascorbic
acid and 0.04% hydrocortisone, according to the manufacturer’s instructions and 1% 100 U/
ml penicillin and 100μg/ml streptomycin. The cells were split at 90% confluency onto fresh
collagen-coated flasks or plates (12 or 24 well) for experiments, with medium changed every 2-
3days.
Human microvascular endothelial cells (MVEC) originally derived from lung were
obtained from ScienCell and grown in the same conditions as stated above. bEnd.3 mouse
brain endothelial cells were supplied by the European culture collection and grown in DMEM
with 10%FBS, penicillin and streptomycin. All cell cultures were maintained at 37˚C in air
with 5% CO2.
Cytometry and analysis of peptide endocytosis
hCMEC/D3, bEnd.3 or MVEC (Lonza, CC-2527) cells were grown to confluence in a 12-well
or 24-well plate and washed 2x with HBSS at 37˚C before being treated with stated concentra-
tions of each peptide (equal fluorescence intensity). Treated cells were incubated at 37˚C for
30mins–3hrs. They were then washed twice with warmed HBSS and detached from their wells
by adding 500μl of trypsin + EDTA solution (Sigma-Aldrich, Dorset, UK, Cat No. T3924) and
incubating at 37˚C for 5mins. The contents of each well were harvested into individual 15ml
Falcon tubes. The wells were washed for remaining cells by adding another 1ml of HBSS,
which was then also added to the respective tubes. The tubes were centrifuged for 5mins at
4˚C and 1500 RPM. All but the cell pellet was then removed and the cells washed in 1ml cold
HBSS.
The cells were centrifuged under the same conditions and all but the cell pellet removed.
The cells were resuspended in 300μl HBSS and the total solution transferred to chilled FACS
tubes. The cytometer (FACscan, Becton & Dickinson) was set to capture 10,000 cells in the
FSC/SSC gate, and the gain voltage on the FL1 detector (fluorescein) adjusted so that 90% of
Table 1. Characteristics of peptides.
Peptide Sequence Structure Source
Pep-1 Fitc-GAWSIIDCSMNYCLYIEG Cyclic, disulphide bond C-C [22]
Pep-2 Fitc-GAIHCHPQGDQSVSFCWR Cyclic, disulphide bond C-C
Pep-10 Fitc-GALHECTYYWWGLDCSFR Cyclic, disulphide bond C-C
Pep-10-M Fitc-GALHEDTYYWWGLDKSFR Cyclic, peptide bond between D-K New
Pep-R1 Fitc-GACENWWGDVCGAGAG Cyclic, disulphide bond C-C [23]
Pep-R2 Fitc-GACLSSRLDACGAGAG Cyclic, disulphide bond C-C
Pep-L THRPPMWSPVWPSK-Fitc Linear,Fitc attached to K side chain [21]
Pep-L� THRPPMWSPVWPCS -CS added for exchange reaction New
https://doi.org/10.1371/journal.pone.0252341.t001
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untreated cells gave a FL1 value <10. The median fluorescence values were taken from each
culture as a single data point.
Each sample was analysed in triplicate (separate cultures) and each experiment carried out
2–4 times with concordant results. FACS histograms are representative and the data compiled
to show the mean ±SEM of the median fluorescence of each of the triplicate cultures.
Nanoparticles and quantitation of gold
Gold nanoparticles (NP), obtained from Midatech Pharma Plc, were synthesised using a modi-
fied Brust-Schiffrin method and capped during synthesis with thiol-C2-glucose [25]. Gold in the
NPs was measured by the following spectrophotometric method in 96 well plates. A total volume
of 10μl of sample was applied to each well. To this, 30μl of 50% fresh, cold Aqua Regia (mixture
of conc. nitric acid and conc. hydrochloric acid in a 1:3 Molar ratio) was applied. The liquid was
mixed by gentle tapping and left to stand for 1 minute to atomise the gold. Next, 150μl of 2M
NaBr was added. The absorbance was read on a plate reader OPTIMA FluoSTAR at 382nm
against a gold standard (Sigma). Each sample and the standards were tested in triplicate.
Ligand exchange reaction
A ligand exchange reaction occurs when AuNPs (with a coating of thiol-linked sugar residues)
are mixed with ligands containing a free thiol group, in aqueous solution. In this case,
10.2nmol of NP (defined as 100 gold atoms/core) was combined with the appropriate ratio of
ligand, ie in the 1:1.5 exchange reaction mixture, 15.3nmol of peptide, Pep-L (1722MW) =
2.6μl of 10mg/ml stock or Pep-L+Fitc (2080MW) = 3.2μl of 10mg/ml stock, in a 15ml falcon
tube. This mixture was vortexed 15-30secs and then incubated at 37˚C at 600rpm for 3hrs in a
PHMT Grant-bio Thermo Fisher heat/shaker block. All samples were then spun at 17,000G
for 30secs after which samples were spun-filtered 3 times in 15ml 10kDa MWCO vivaspins at
4000G and resuspended in ddH2O.
Transport assay
Transport of the nanoparticles was measured using a 3-dimensional hydrogel model of the
blood-brain barrier in 24-well plates (1cm2, Greiner). The hydrogels were prepared with 2.0mg/
ml type 1 rat tail collagen (First Link, Wolverhampton, UK) in 0.6% acetic acid in water. The
gels (0.5ml per well) were set by neutralisation with 1M NaOH and equilibrated with MEM.
When set, hCMEC/D3 cells were seeded at a density of 80,000–100,000 cells per well and incu-
bated for 2–3 days in culture medium. After the monolayer was formed, the endothelial cells
were switched to a medium without VEGF for 3 days to form tight junctions. The nanoparticles
were applied to the surface of the endothelium at a final concentration of 8μg/ml (gold) and
incubated for 3 hours at 37˚ C. After the incubation, the media was removed, cells washed 2x
with HBSS and the endothelial cells removed with a brief collagenase digestion (1mg/ml) until
the monolayer detached from the collagen (~10mins). The collagen gel was then fully digested
with collagenase to recover nanoparticles that had crossed the endothelium. The endothelium
and collagen digest were analysed for gold by ICP-Q-MS. This culture system has the advantage
that nanoparticles released from the basal surface of the endothelium (after transcytosis) are not
trapped on a filter or in the basal lamina, but diffuse away from the endothelium.
Statistical analysis
All FACS analyses were carried out with independent cell cultures in triplicate and median
fluorescence value of 10,000 cells from each culture was measured. Data is shown as the mean
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of the median fluorescence, ±SEM. Statistical analysis was carried out using Prism-7 software,
with ANOVAR followed by Dunnett’s multiple comparison test, or Student’s t-test as appro-
priate. Each experiment was repeated 3 times with concordant results.
Results
A set of peptides known to bind to the TfR and peptides that selectively bind brain endothe-
lium were synthesised with a fluorescent tag (Fitc) on either the N- or C-terminal amino acids
(Table 1). Specific fluorescence of the peptides was measured by fluorimetry; to facilitate com-
parison between the peptides they were applied at concentrations producing equal fluores-
cence in the tracking studies (S1 Table). In addition an equivalent amount of Fitc-dextran
(70kDa) was included as a control for non-specific endocytosis (ie not receptor mediated).
These peptides were applied to the human brain endothelial cell line hCMEC/D3 to establish
an appropriate time-point and concentrations for later experiments. Peptides were first incu-
bated with the endothelium for 0–3 hours. Unbound peptides were removed, the endothelial
cells released by trypsinisation and the endocytosed peptides detected and quantitated by flow
cytometry. All FACS histograms showed a single peak, and median fluorescence values were
derived from each histogram. Data points represent the mean (n = 3) of the median fluores-
cence values. The time course of internalisation is shown in Fig 1A.
The results in all cases showed a progressive rate of uptake, which was fastest in the first
hour, but the values from each peptide differed considerably. The time course did not saturate
(no plateau), so the 3hr time-point was chosen for subsequent experiments, as it gave the larg-
est differential between different peptides. A comparison of peptide uptake at 3 hours showed
that Pep-1, Pep-10 and Pep-L showed highest rates of endocytosis (Fig 1B). Pep-2 also showed
significant uptake, but the two peptides isolated by in vivo binding (Pep-R1 and Pep-R2), were
not consistently significantly higher than the Fitc-dextran control. Note that the FACS data
measures the amount of accumulated endocytosed peptide, not the position of the Tfr, so the
results do not give information on the subcellular location of the receptor or its traffic path-
ways through the cell.
Some variation in the absolute values was seen in independent experiments, but the overall
ranking of the peptide-uptake was always Pep-L, Pep-1, Pep-10 > Pep-2> Pep-R1,Pep-R2.
Peptide endocytosis by hCMEC/D3 cells was then compared with uptake by another
human microvascular endothelial cell line (MVEC) and a mouse brain endothelial cell line,
bEnd.3 (Fig 2). For transport studies, it is important that targeting peptides can bind to both
human and mouse TfR. This allows in vitro studies on human cells to be followed by in vivo
studies in rodents. The results show that Pep-1, Pep-2 and Pep-10 also bind to mouse brain
endothelium and the MVECs. (It has previously been reported that Pep-L also recognises
mouse TfR [21]. However, there were some notable differences in the binding of individual
peptides to different cell types: Pep-1 and Pep-R2 both bound relatively strongly to MVECs
and Pep-10 bound more strongly to the mouse line than to the two human cell lines. Two fac-
tors may explain these results. MVEC, which are rapidly dividing cells, express high levels of
the TfR as detected by cell-surface ELISA and Pep-10 has been shown to bind significantly
more strongly to mouse TfR than human TfR [22].
The binding of Pep-1, Pep-2, Pep-10, and Pep-L to hCMEC/D3 was examined in more
detail. The initial studies (Figs 1–3) were carried out with peptides at equivalent fluorescence
to facilitate comparison of the peptides by FACS (S1 Table). Uptake of peptides was directly
proportional to the concentration applied in the range 1–30μg/ml (S1 Fig) indicating that the
mechanism of internalisation does not saturate at these concentrations.
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The uptake assays were then repeated in the presence of variable levels of bovine serum
albumin (BSA) or human Tf (Fig 3). Uptake of Pep-L was strongly inhibited in the presence of
8mg/ml serum albumin, a concentration approximately equivalent to 20% of the level in
serum. Pep-L has a high proportion of hydrophobic amino acids and a net positive charge (S1
Table), so it is likely that binding to negatively charged serum albumin reduces the effective
concentration of free-peptide available for binding to the TfR.
Pep-10 showed dose-dependent inhibition of binding to the endothelium in the presence of
Tf; 1mg/ml Tf is a concentration similar to that found in normal serum. The result suggests
that Pep-10 binds to the TfR close to the Tf binding site, but there was still some uptake, even
at the highest level of Tf. Pep-1 uptake was weakly inhibited with Tf. Pep-L was also partly
inhibited by Tf, but did not show a simple dose-dependent effect.
In a separate set of experiments (S2 Fig) it was confirmed that treatment of hCMEC/D3
cells with Tf did not alter expression of the TfR on the membrane surface of hCMEC/D3 cells.
Fig 1. Endocytosis of peptides by hCMEC/D3 cells. A. Uptake of peptides by hCMEC/D3 cells over 3 hours
measured by FACS. Values are mean ± SEM of the median fluorescence from 3 replicate cultures. B. Mean ± SEM of
the median fluorescence of 6 peptides binding to hCMEC/D3 cells. Data is derived from 3 biological replicates and 3
technical replicates of each culture, analysed by Dunnet’s multiple comparison test, comparing each peptide with the
FITC-dextran non-specific endocytosis control. � P<0.05, ���� P<0.0001.
https://doi.org/10.1371/journal.pone.0252341.g001
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Hence the inhibition of Pep-10 uptake caused by Tf was not due to a loss of the TfR, but com-
petition for the receptor.
One potential use of the TfR-targeting peptides is to improve uptake of nanocarriers into
cells or tissues expressing the TfR. Binding of cargo molecules or peptides onto gold nanoparti-
cles is readily effected by the exchange reaction, in which a ligand with a free–SH group
exchanges, in reducing conditions, with a ligand bound to the gold core by Au-S bonds. How-
ever cyclic peptides with a loop held by a disulphide bond between cysteine residues cannot be
used in the exchange reaction, because the conditions required would break open the loop and
the free–SH groups could then attach to the nanoparticle, thereby destroying the peptide struc-
ture. In order to circumvent this limitation, one possible solution is to substitute the Cys-Cys
bridge holding the loop with an alternative chemical bond, that is stable in reducing condi-
tions. To determine if this approach was feasible a variant of Pep-10 was synthesised (Pep-
10M) in which the two Cys residues were substituted by aspartic acid (D) and lysine (K) resi-
dues, cross-linked by a peptide bond between their side chains (Table 1). The uptake of Pep-
10M by hCMEC/D3 cells was then compared with the original Pep-10 (Fig 4). The FACS his-
togram demonstrated that the modified peptide could still bind to the cells, although it was
less effective than the original peptide.
From the initial experiments Pep-L appeared to have the best potential for targeting to
brain endothelium. To demonstrate the potential, a variant of Pep-L was synthesised with the
addition of a cysteine residue near the C-terminus, to allow it to engage in an exchange reac-
tion (Table 1, Pep-L�). The modified peptide had the two C-terminal residues, replaced with
-CS to allow attachment to the NP and the Fitc (if present) placed on the N-terminus. The pep-
tide was attached via the exchange reaction to 2nm core diameter gold nanoparticles with a
thiol-C2-glucose ligand shell. In the reaction, the cysteine of the Pep-L� displaced some of the
C2-glucose residues. The reaction was performed with two different molar ratios of nanoparti-
cle:peptide (in these conditions, 1–4 ligands may exchange with the C2-glucose on each nano-
particle) and free peptide was removed on a spin filter. The nanoparticles were applied to a
model of the blood-brain barrier with hCMEC/D3 cells on a collagen gel [26]. This model
allows free diffusion of nanoparticles away from the basal membrane of the endothelium and
Fig 2. Endocytosis of TfR peptides by different endothelial cell lines. Endocytosis of peptides by hCMEC/D3, MVEC and bEnd.3
cells analysed by FACS. Data shown is the mean ±SEM of the median fluorescence of 3 biological replicates. Binding of each peptide
on different cell types was compared using an unpaired t-test. (��� = p<0.001, �� = p<0.01 and � = p<0.05).
https://doi.org/10.1371/journal.pone.0252341.g002
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electron micrographs demonstrate that these gold glyconanoparticles cross the endothelium
by a combination of vesicular and cytosolic transcytosis, with the relative amounts moving by
each route, dependent on the formulation of the nanoparticle and cargo molecules [27]. The
amount of gold recovered in the cells and in the gel is shown in Fig 5. At the ratio of NP:pep-
tide 1:1.5, significantly more gold was found in both the cell layer and the collagen gel.
Although this system was not optimised, it demonstrates that the addition of a TfR targeting
peptide can enhance endocytosis and transcytosis of a gold nanocarrier across the brain endo-
thelial cells.
Discussion
The ability to target a therapeutic agent to specific cells or tissues is a major goal in the devel-
opment of effective treatments for disease. Polypeptides are particularly attractive for this pur-
pose, as they can be synthesised in quantity and at high purity. They are also relatively small in
comparison with antibody and antibody-fragments used for targeting receptors or in compari-
son with the nanocarriers currently under development. Cyclic polypeptides with 4–8 amino-
acid residues in a loop closed by a disulphide bond between two cys residues have been devel-
oped against a number of receptors including the TfR [21, 22]. Typically these polypeptides are
Fig 3. Inhibition of peptide uptake by BSA and transferrin. Endocytosis of TfR-binding peptides by hCMEC/D3 cells in the
presence of different amounts of BSA (A) or transferrin (B). Data are the mean ±SEM (n = 3) of the median fluorescence of
independent cultures. Data was analysed by Dunnet’s multiple comparison test. � p<0.05, �� p<0.01, ���p<0.001, ���� p<0.0001.
https://doi.org/10.1371/journal.pone.0252341.g003
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10–20 amino acid residues in length (1 – 3kDa) and cyclisation gives structural stability to the
polypeptide loop that binds to the receptor on the target cell. Cyclisation also increases their
resistance to degradation by peptidases.
The TfR, which is selectively expressed on brain endothelium (TfR-2) has been identified
for its potential to transport therapeutic agents across the blood-brain barrier [14, 28]. In this
paper we have investigated four polypeptides originally isolated for their binding to human
and mouse TfR (Pep-1, Pep-2, Pep-10, Pep-L). Two polypeptides that selectively bound to
brain endothelium in vivo were also investigated (Pep-R1, Pep-R2). Since Pep-R2 has homol-
ogy (-WWG-) in the loop with Pep-10, it is likely that Pep-R2 also binds to the TfR. Several
other peptides isolated by binding to TfR also have this motif in the centre of the loop [22].
Comparison of the binding of the different peptides to the human brain endothelial cell line
hCMEC/D3 demonstrated strong uptake of Pep-1, Pep-10 and Pep-L and lower uptake of
Pep-2 (Fig 2). Pep-R1 and Pep-R2 showed weak uptake which was not consistently signifi-
cantly higher than the dextran control for (non-specific) absorptive endocytosis. Further
examination of the four TfR-binding peptides, showed that albumin inhibited endocytosis of
Pep-L (Fig 3A) which is the most hydrophobic of the set and the only peptide with a positive
charge at neutral pH. Binding to negatively-charged albumin by electrostatic interaction
would reduce the effective concentration of available free Pep-L, and could therefore explain
reduced endocytosis in the presence of albumin. While this may be an advantage in extending
the half-life of a peptide-based therapeutic agent [29] it could prove to be a limitation for the
use of Pep-L as a targeting molecule in serum and other tissue fluids that have high amounts of
albumin. However, when attached to a nanoparticle additional considerations apply. The sur-
face ligands of nanoparticles considerably affects their uptake by endothelial cells in two major
Fig 4. Structural modification of TfR-binding Pep-10. A representative FACS histogram comparing uptake of Pep-
10 and Pep-10M by hCMEC/D3 cells after 3 hours. The inset table shows the mean ± SEM of the median fluorescence
of 3 replicate cultures.
https://doi.org/10.1371/journal.pone.0252341.g004
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ways: acidic or basic groups attract a corona of serum proteins of the opposite charge which
may effectively flip the charge of the nanoparticle [30] and bound proteins can enhance uptake
by the endothelium for both receptor mediated transport (RMT) and absorptive mediated
transport (AMT). Additionally an increase in charge of nanoparticles (positive or negative)
generally increases uptake by the endothelium [31, 32].
Fig 5. Transcytosis of gold NPs with targeting peptide. Recovery of gold in the hCMEC/D3 cells or the collagen gel,
after application of gold NPs with different concentrations of Pep-L� (with or without Fitc) to the apical surface of
hCMEC/D3 cells. Values are mean ± SEM of 6 biological replicates, each with two determinations of gold
concentration. Nanoparticles with bound peptides were compared with C2-glucose-NPs (β-Glu) by paired t-test (�
P<0.05, ��� P<0.001).
https://doi.org/10.1371/journal.pone.0252341.g005
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Of the remaining peptides, Pep-10 endocytosis was inhibited and Pep-1 slightly inhibited
by Tf at concentrations normally found in serum (Fig 3B). Neither peptide was completely
blocked at 1 mg/ml Tf which is approximately a 4-fold molar excess of Tf:peptide. The affin-
ity of Tf with bound iron for the TfR is high and binding induces global changes in the con-
formation of the ectodomain of the receptor [33]. Consequently Tf binding could alter
affinity of the peptides for TfR even if they bind at sites distant from the Tf-binding site. This
is the most likely explanation for the reduction in binding of Pep-1 and Pep-10 in the pres-
ence of free Tf.
Peptides (1-3kDa) have some distinct advantages over larger targeting molecules such as
IgG antibodies (~160kDa) or antibody fragments. Their small size is less likely to alter the
characteristics of a nanocarrier, and they cannot cross-link the receptor. Cross-linking of
receptors often results in trafficking of the receptor through endosomal compartments to lyso-
somes and degradation. For delivery of therapeutic agents it is important that the targeted
receptor remains in the recycling/transcytosis pathways. For this reason monovalent antibody
fragments targeting the Tfr appear to be more effective than whole antibody in delivering
material to the brain [34].
While there are several advantages in the use of targeting peptides, there are potential disad-
vantages; firstly the binding site is small by comparison with, for example, an antibody and
consequently the affinity of the peptide for a receptor is likely to be lower than the affinity of
an antibody; For transcytosis across brain endothelium it has been shown that high affinity
antibodies are less effective than medium affinity antibodies [35, 36], and reducing antibody to
the Tfr can enhance its level of transcytosis [16]. Hence the lower affinity of peptides may actu-
ally be an advantage in targeting therapeutic agents to the brain.
Another possible limitation of these peptides is that the disulphide bond that cyclises them
can be cleaved in reducing conditions. To test whether this could be overcome, a variant of
Pep-10 was produced, in which the disulphide bond between Cys residues was replaced with a
peptide bond between Asp and Lys residues. The length of the cross-link is longer than the dis-
ulphide bond, so it was anticipated that this would affect the configuration of the loop and con-
sequently binding affinity to the TfR and endocytosis by the endothelium. The structural
modification did indeed reduce binding, but only partially (Fig 4) which indicates that more
stable variants of the cyclic peptides could be synthesised and still retain TfR-binding activity.
Other chemistries for cyclising peptides have been developed and could be substituted where
the disulphide bond presents problems, as in the exchange reaction described here. However,
any alteration in the size of the loop or the length of the cross-bridge is likely to affect binding
of the peptide to the receptor.
As proof of principle Pep-L was attached to 2nm gold nanoparticles (NP) by exchange
with the C2-glucose coat on the NPs. At the higher molar ratio in the exchange reaction, the
peptide significantly enhanced NP-endocytosis by the brain endothelium and increased the
amount that had crossed the endothelium and localised in the collagen matrix beneath the
basal membrane (Fig 5). Clearly, any use of peptides for targeting therapy would require
optimisation for each therapeutic agent. For example, gold NPs can carry more than one
peptide moiety, which could increase their avidity for the TfR. Also, the affinity of binding of
the agent to the TfR could affect its intracellular trafficking. In the case of brain endothelium
the aim is to promote transcytosis, and moderate affinity binding is likely to be advanta-
geous, since the peptide must release from the TfR if it is to carry material across the endo-
thelium. Conversely, if one used the peptides to target a cytotoxic agent to the TfR on a
tumour cell, high affinity binding would be preferred in order to maximise internalisation of
the agent in the target cell.
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Conclusions
Four peptides, Pep-1, Pep-2, Pep-10 and Pep-L all have potential for targeting the human and
mouse transferrin receptor (TfR). The linear peptide, Pep-L is inhibited by albumin, which
may limit its utility in tissue fluids with high levels of albumin. The cyclic peptides, Pep-1, Pep-
2 and Pep-10 bind to both human and mouse TfR and are taken up at different levels of effi-
ciency by endothelial cells expressing the TfR. Pep-1 and Pep-10, which show highest levels of
endocytosis, appear to bind near the Tf-binding site on the receptor. Modification of Pep-10
by replacing the disulphide bond of the loop with a peptide bond, reduces the susceptibility to
reducing conditions, enabling ligand exchange and increasing stability in vivo. A peptide with
a single free thiol can be attached to gold nanoparticles by a simple exchange reaction and this
enhances transcytosis across brain endothelium and hence may be used to increase delivery of
therapeutic agents across the blood-brain barrier.
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Methodology: Conor McQuaid, David Male.
Project administration: David Male.
Supervision: Ignacio Romero, David Male.
Writing – original draft: Conor McQuaid, David Male.
Writing – review & editing: Conor McQuaid, David Male.
References
1. Cummings J, Lee G, Ritter A, Zhong K. Alzheimer’s disease drug development pipeline: 2018. Alzhei-
mer’s Dement Transl Res Clin Interv. 2018; 4:195–214. https://doi.org/10.1016/j.trci.2018.03.009
PMID: 29955663
2. Tsumoto K, Isozaki Y, Yagami H, Tomita M. Future perspectives of therapeutic monoclonal antibodies.
Immunotherapy. 2019; 11:119–27. https://doi.org/10.2217/imt-2018-0130 PMID: 30730271
3. Nam J-S, Lee S-S, Chakraborty C, Sharma G, Bhattacharya M, Sharma AR. Advances in nanocarriers
enabled brain targeted drug delivery across blood brain barrier. Int J Pharm. 2019; 559:360–72. https://
doi.org/10.1016/j.ijpharm.2019.01.056 PMID: 30721725
4. Lajoie JM, Shusta EV. Targeting receptor-mediated transport for delivery of biologics across the blood-
brain barrier. Annu Rev Pharmacol Toxicol. 2015; 55:613–31. https://doi.org/10.1146/annurev-
pharmtox-010814-124852 PMID: 25340933
PLOS ONE Transferrin-receptor binding polypeptides
PLOS ONE | https://doi.org/10.1371/journal.pone.0252341 June 4, 2021 12 / 14
5. Daniels TR, Bernabeu E, Rodrı́guez JA, Patel S, Kozman M, Chiappetta DA, et al. The transferrin
receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012;
1820:291–317. https://doi.org/10.1016/j.bbagen.2011.07.016 PMID: 21851850
6. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: Biology
and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006; 121:144–58.
https://doi.org/10.1016/j.clim.2006.06.010 PMID: 16904380
7. Paterson J, Webster CI. Exploiting transferrin receptor for delivering drugs across the blood-brain bar-
rier. Drug Discov Today Technol. 2016; 20:49–52. https://doi.org/10.1016/j.ddtec.2016.07.009 PMID:
27986223
8. Bourassa P, Alata W, Tremblay C, Paris-Robidas S, Calon F. Transferrin receptor-mediated uptake at
the blood-brain barrier is not Impaired by Alzheimer’s disease neuropathology. Mol Pharm. 2019;
16:583–94. https://doi.org/10.1021/acs.molpharmaceut.8b00870 PMID: 30609376
9. Georgieva J V, Hoekstra D, Zuhorn IS. Smuggling drugs into the brain: An overview of ligands targeting
transcytosis for drug delivery across the blood–brain barrier. Pharmaceutics. 2014; 6:557–83. https://
doi.org/10.3390/pharmaceutics6040557 PMID: 25407801
10. Pulgar VM. Transcytosis to cross the blood brain barrier, new advancements and challenges. Front
Neurosci. 2019; 12:1019. https://doi.org/10.3389/fnins.2018.01019 PMID: 30686985
11. Crawford L, Rosch J, Putnam D. Concepts, technologies, and practices for drug delivery past the
blood–brain barrier to the central nervous system. J Control Release. 2016; 240:251–266. https://doi.
org/10.1016/j.jconrel.2015.12.041 PMID: 26724368
12. Pardridge WM. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx. 2005; 2:3–14.
https://doi.org/10.1602/neurorx.2.1.3 PMID: 15717053
13. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-
brain barrier. Neurobiol Dis. 2010; 37:13–25. https://doi.org/10.1016/j.nbd.2009.07.030 PMID:
19664713
14. Johnsen KB, Burkhardt A, Melander K, Kempen PJ, Vejlebo JB, Siupka P et al. Targeting transferrin
receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo
transport into the brain parenchyma. Sci Rep. 2017; 7:10396. https://doi.org/10.1038/s41598-017-
11220-1 PMID: 28871203
15. Moura RP, Martins C, Pinto S, Sousa F, Sarmento B. Blood-brain barrier receptors and transporters: an
insight on their function and how to exploit them through nanotechnology. Expert Opin Drug Deliv.
2019; 16:271–285. https://doi.org/10.1080/17425247.2019.1583205 PMID: 30767695
16. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, et al. Boosting brain uptake of a therapeutic antibody
by reducing its affinity for a transcytosis target. Sci Transl Med. 2011; 3 (84): 84ra44. https://doi.org/10.
1126/scitranslmed.3002230 PMID: 21613623
17. Gang D, Kim DW, Park HS. Cyclic peptides: Promising scaffolds for biopharmaceuticals. Genes 2018;
9:557. https://doi.org/10.3390/genes9110557 PMID: 30453533
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